AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

54.34USD
8:36pm IST
Price Change (% chg)

$-0.14 (-0.26%)
Prev Close
$54.48
Open
$54.16
Day's High
$54.43
Day's Low
$54.16
Volume
733,908
Avg. Vol
1,541,374
52-wk High
$58.27
52-wk Low
$42.25

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidem... (more)

Overall

Beta: --
Market Cap (Mil.): $86,736.20
Shares Outstanding (Mil.): 1,592.07
Dividend: 0.42
Yield (%): 3.08

Financials

  ABBV.N Industry Sector
P/E (TTM): 21.17 36.00 36.40
EPS (TTM): 2.57 -- --
ROI: 19.33 19.00 18.27
ROE: 108.18 19.78 19.15
Search Stocks

U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 billion deal

LONDON - U.S. drugmaker AbbVie Inc bought Dublin-based Shire Plc on Friday in a 32 billion pound ($54.7 billion) deal that will allow it to slash its tax bill by relocating to Britain. | Video

19 Jul 2014

U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 bln deal

LONDON - U.S. drugmaker AbbVie Inc bought Dublin-based Shire Plc on Friday in a 32 billion pound ($54.7 billion) deal that will allow it to slash its tax bill by relocating to Britain.

19 Jul 2014

AbbVie’s Shire merger backed with 13.5 billion pound bridge loan

LONDON - U.S. drugmaker AbbVie’s 32 billion pounds acquisition of Dublin-based Shire Plc is backed with a 13.5 billion pounds ($23.03 billion) bridge loan, according to the company's filing with the Securities and Exchange Commission in the US.

18 Jul 2014

RLPC-AbbVie's Shire merger backed with 13.5 bln stg bridge loan

LONDON, July 18 - U.S. drugmaker AbbVie's 32 billion pounds acquisition of Dublin-based Shire Plc is backed with a 13.5 billion pounds ($23.03 billion) bridge loan, according to the company's filing with the Securities and Exchange Commission in the US.

18 Jul 2014

AbbVie CEO says tax is not primary reason for buying Shire

LONDON - Pharmaceutical firm AbbVie's chairman and chief executive said tax benefits were not the main reason it bought London-listed Shire .

18 Jul 2014

AbbVie CEO says tax is not primary reason for buying Shire

LONDON, July 18 - Pharmaceutical firm AbbVie's chairman and chief executive said tax benefits were not the main reason it bought London-listed Shire.

18 Jul 2014

Deals of the day- Mergers and acquisitions

(Adds Abbvie, Allergan, TRW Auto, Telefonica, Bingham McCutchen, Fred's, GTECH, Slovak Telekom, Cliffs Natural, Rosneft, Woolworths, Koncar, Dong Energy ; updates Fiat Chrysler)

18 Jul 2014

Shire, AbbVie to announce $53 billion merger by Friday: sources

- Shire Plc and U.S. drugmaker Abbvie Inc plan to announce a $53 billion merger as soon as Friday morning, two people said on Thursday.

18 Jul 2014

CORRECTED-UPDATE 1-Shire, AbbVie to announce $53 bln merger by Friday -sources

(Corrects paragraph 7 to show failed bid for AstraZeneca happened in May not June))

18 Jul 2014

CORRECTED-Shire, AbbVie to announce $53 billion merger by Friday -sources

(Corrects 6th paragraph to show Pfizer's failed bid for AstraZeneca happened in May not June)

17 Jul 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $102.28 +0.09
Pfizer Inc. (PFE.N) $30.36 -0.03
Novartis AG (NOVN.VX) CHF80.40 +0.20
Merck & Co., Inc. (MRK.N) $58.11 0.00
Roche Holding Ltd. (ROG.VX) CHF268.30 +1.80
Abbott Laboratories (ABT.N) $42.85 -0.12
Eli Lilly and Co (LLY.N) $64.42 +0.17

Earnings vs. Estimates

Search Stocks